| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | LYC2; LYZD1; KAAG648; PRO1278; bA534G20.1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human LYZL1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LYZL1抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*LYZL1作为膀胱癌潜在生物标志物的免疫组化研究*
**作者**：Zhang Y, Li H, Wang X, et al.
**摘要**：该研究通过制备LYZL1特异性抗体，分析其在膀胱癌组织中的表达水平。结果显示，LYZL1在肿瘤组织中显著高表达，并与患者预后不良相关，提示其可能作为膀胱癌诊断或治疗的潜在靶点。
---
2. **文献名称**：*LYZL1在人类精子发生中的功能及其抗体应用*
**作者**：Li R, Chen J, Liu Y, et al.
**摘要**：利用LYZL1多克隆抗体进行免疫荧光定位，发现LYZL1主要表达于精子顶体区域。功能研究表明，LYZL1缺失会导致精子形态异常，提示其在精子成熟过程中起关键作用，为男性不育机制研究提供依据。
---
3. **文献名称**：*基于LYZL1抗体的血清ELISA检测在男性不育中的应用*
**作者**：Wang T, Zhang L, Zhou M, et al.
**摘要**：研究开发了一种基于LYZL1抗体的ELISA检测方法，用于评估男性不育患者血清中LYZL1水平。结果显示，LYZL1水平与精子质量显著相关，表明该抗体在临床诊断中具有潜在应用价值。
---
**注**：以上文献为示例性概括，实际引用需以具体发表的论文为准。建议通过PubMed或Web of Science以“LYZL1 antibody”为关键词检索最新文献。
The LYZL1 (Lysozyme-like 1) antibody is a research tool designed to detect and study the LYZL1 protein, a member of the lysozyme superfamily. Lysozymes are traditionally known for their antimicrobial properties, but LYZL1 exhibits distinct structural and functional characteristics. It is predominantly expressed in the male reproductive system, particularly in the epididymis, where it is thought to play a role in sperm maturation and fertility. Studies suggest LYZL1 may bind to sperm surfaces, influencing motility or fertilization capacity. Dysregulation of LYZL1 has been implicated in male infertility, making it a potential biomarker for reproductive health assessments.
Beyond reproductive biology, LYZL1 antibodies have gained attention in cancer research. Elevated LYZL1 expression has been observed in certain malignancies, including gliomas and gastric cancers, where it may correlate with tumor progression or therapy resistance. The antibody enables localization and quantification of LYZL1 in tissues or cell lines, aiding mechanistic studies. Commercially available LYZL1 antibodies are typically developed in rabbit or mouse hosts using immunogenic peptide sequences. Validation often includes Western blotting, immunohistochemistry, and ELISA. However, researchers must verify specificity due to potential cross-reactivity with other lysozyme family members. Ongoing research aims to clarify LYZL1's dual roles in physiological and pathological contexts, with therapeutic applications under exploration.
×
